Why We Invested in Deka Biosciences: Pioneering Precision Medicine for Solid Tumors
Deka Biosciences is a Maryland-based biotech company making strides in cancer treatment. Deka is pioneering a new therapeutic platform designed for solid and hematological tumors, as well as for patient suffering from inflammatory disease, aiming to enhance cytokine delivery to the affected tissues while significantly minimizing toxicity risks for patients. What makes this investment particularly special to us is the local connection: Deka’s drug is manufactured in Oklahoma City by Cytovance Biologics and Wheeler Bio, and the OU Health Stephenson Cancer Center is one of their clinical trial sites.
Strategic Value: Precision Medicine for Solid Tumors
Deka’s approach to precision medicine aligns perfectly with our investment philosophy of supporting companies that prioritize patient-centered innovations. Recognizing that patient responses can vary, Deka is developing a blood test to predict individual responses to their treatments, enabling better patient selection for clinical trials and eventual treatment.
By tailoring treatments to patient needs, Deka’s platform holds immense potential for expanding the therapeutic options available for cancer care. Their technology lays the groundwork for the development of alternative drug versions that could eventually target 100% of patients with a specific cancer type, enhancing outcomes across the board.
Why Deka? Promising Science and a Visionary Founder
Our excitement for Deka began with recognizing their underlying science is very strong and is tackling a very large market in a unique way. Led by seasoned scientist and biotech entrepreneur John Mumm, Deka’s leadership combines scientific expertise with a keen sense of financial strategy—a combination that is essential for sustained growth in the biotech industry. Our initial investment in Deka came in mid-2023 after they demonstrated promising preclinical results, showcasing both potent tumor response and reduced toxicity compared to earlier, less successful treatments. In mid-2024, we provided further support as Deka moved forward with Phase 1 clinical trials. With this investment, Deka is on track to produce a Phase 2-ready clinical asset in 2025, marking a significant milestone in developing a precision-based treatment for solid tumors.
A Bright Future Ahead
Deka’s dedication to delivering more effective, personalized treatments controlling each patient’s immune system has us very excited about the future. With strong science, a clear market need, and robust leadership, Deka is well-positioned to become a leading force in the field of precision oncology and inflammation. We’re proud to support Deka’s journey and look forward to seeing the positive impact their work will have on patients and the broader field of cancer treatment.
